secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001104659-25-018234
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma: pediatric Netherton Syndrome patient shows dramatic skin healing after 2 weeks of QRX003
--------------------------------------------------------------------------------

- IGA score improved from 7 to 1-2 (0-10 scale) after two weeks of whole-body QRX003 treatment.
- Pruritus (itch) score reduced from 5 to 1; patient stopped all antihistamines, glucocorticoids, and antivirals.
- Patient now experiences zero nightly sleep disturbances for first time; no adverse events reported.
- First pediatric patient data from ongoing Investigator Pediatric Netherton Syndrome study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925018234/0001104659-25-018234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925018234/tm257848d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer